TIMP1 and breast carcinoma: Recently, we reported the clinical value of this technology to evaluate the expression of MMP-1, -2, -7, -9, -11, -13 and –14, and TIMP-1, -2 and 3, in breast cancer (Vizoso et al, 2007).